New and experimental HIV treatments: latest news

New and experimental HIV treatments features

New and experimental HIV treatments in your own words

New and experimental HIV treatments news from aidsmap

More news

New and experimental HIV treatments news selected from other sources

  • Abivax releases positive top line data from ABX464-005 phase 2a study in HIV infection

    “These findings show, for the first time, that ABX464 has the ability to reduce HIV DNA in both blood and rectal tissue reservoirs,” said Dr Jean-Marc Steens, Chief Medical Officer at ABIVAX. “The longer 12 week duration of treatment with ABX464 was safe and generally well tolerated and supports extended dosing.”

    04 July 2018 | Abivax press release
  • European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

    Today’s decision makes BIC/FTC/TAF Gilead’s third FTC/TAF-based STR approved in the European Union in the past three years.

    25 June 2018 | Gilead press release
  • First Multipurpose Gel Designed to Prevent HIV, HSV, and HPV Simultaneously in Women and Men Advances in Clinical Trials

    A new Phase I study of the Population Council’s multipurpose prevention technology (MPT) gel PC-1005, launching this week, will examine the safety of the gel when used rectally by both men and women. If proven effective, PC-1005 gel would be the first product to prevent three incurable sexually transmitted infections (STIs)—HIV, herpes simplex virus (HSV), and human papillomavirus (HPV)—when used either vaginally or rectally.

    25 June 2018 | Population Council
  • GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

    GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world’s leading AIDS conference next month by showcasing detailed results from its new two-drug treatment.

    25 June 2018 | Reuters
  • GSK's two-drug HIV treatment meets main goal in late stage studies

    GlaxoSmithKline’s two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field. The combination of dolutegravir and lamivudine was shown to be as effective as a dolutegravir-based combination of three drugs, GSK’s majority-owned ViiV Healthcare said on Thursday.

    15 June 2018 | Reuters
  • ART Simplification Does Not Affect Systemic Inflammation in Virologically Suppressed HIV

    For virologically suppressed patients infected with HIV, switching to a dual antiretroviral maintenance therapy of atazanavir/ritonavir plus lamivudine does not affect plasma markers of systemic inflammation, according to results published in the Journal of Antimicrobial Chemotherapy.

    15 June 2018 | Infectious Disease Advisor
  • ViiV Healthcare reports positive results for landmark phase III studies for dolutegravir and lamivudine

    ViiV Healthcare today announced positive headline results from its phase III GEMINI study programme. The studies (GEMINI-1 and GEMINI-2) are designed to evaluate the safety and efficacy of a two-drug regimen (2DR) of dolutegravir and lamivudine compared to a three-drug regimen of dolutegravir and two nucleoside reverse transcriptase inhibitors, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), in treatment naïve HIV-1 infected adults with baseline viral loads less than 500,000 copies per ml.

    15 June 2018 | ViiV Healthcare press release
  • Single Shot of PRO 140 mAb Cuts HIV Load in Two Thirds on Failing ART

    PRO 140, a once-weekly subcutaneous monoclonal antibody (mAb), lowered viral loads by a half-log or more in two thirds of phase 2b/3 trial participants after an initial injection in combination with a failing antiretroviral regimen [1]. An extension study is testing longer-term response to PRO 140 in people using it with other antiretrovirals.

    11 June 2018 | National AIDS Treatment Advocacy Project
  • Is the World Ready for Long-Acting HIV Treatment?

    "As we look at this question [of] where do long-acting antiretrovirals fit into the armamentarium," commented Carl Dieffenbach, the director of the Division of AIDS within the National Institute of Allergy and Infectious Diseases, "we have to ask ourselves the question: What problems are long-acting or sustained-release formulations solving, and what problems or concerns are the introduction of these type of formulations actually creating?"

    11 June 2018 | The Body Pro
  • China approves Albuviritide: first domestically developed, long-acting injectable anti-HIV drug

    China has approved the first domestically developed, long-acting injectable HIV drug Albuvirtide, which could be a boon to tens of thousands of HIV/AIDS patients in the country, the official media reported. The drug, approved by the China Food and Drug Administration, can block the fusion of the virus and host cell membranes, interrupting the HIV life cycle in its earliest stage.

    06 June 2018 | Firstpost
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.